Pediatrix Medical Group, Inc. (MD) · Oct 29, 2026 · Earnings

Pediatrix earnings beat as EBITDA slips, outlook floor rises

Beat — Adjusted EPS $0.72 vs ~$0.65 consensus

Pediatrix earnings beat Q3 expectations and lifted the low end of 2026 EBITDA guidance, though same-unit growth and margins remain soft.

Pediatrix is still executing a shift toward hospital-based and maternal-fetal medicine services, while using acquisitions and revenue-cycle changes to rebuild growth and efficiency. That backdrop was already known; this quarter mainly tests whether those moves are producing cleaner operating leverage.

The quarter beat the published bar, but not by a wide margin. Adjusted EPS was $0.72 versus a published consensus of about $0.65, while revenue was $501.4 million versus roughly $498.2 million expected. The filing also says volume and pricing were ahead of management’s expectations:

Q3 2026Q3 2025Consensus
Net revenue (Financial Highlights)$501.4M (+1.7%)$492.9M~$498.2M
Adjusted EPS (Adjusted EPS reconciliation)$0.72 (+7.5%)$0.67~$0.65
Adjusted EBITDA (Adjusted EBITDA reconciliation)$85.5M (-2.1%)$87.3M
Same-unit revenue (Operating Results)+0.6%

The quality of the beat is mixed because operating leverage deteriorated. Revenue rose 1.7%, but adjusted EBITDA fell 2.1% as salaries and other costs grew faster than the existing business; the company explicitly attributed the decline to higher expenses relative to revenue growth at existing units. Same-unit revenue increased only 0.6%, with patient volume contributing 0.3%, while hospital-based services and NICU days both declined year over year.

The most important incremental signal is a higher EBITDA floor. Pediatrix moved full-year 2026 Adjusted EBITDA guidance to $290 million-$300 million from the previously reaffirmed $280 million-$300 million range, raising the low end while leaving the ceiling unchanged. That suggests confidence in the earnings floor, but not a broad acceleration in the business.

Buybacks helped per-share results, while cash generation was softer. Weighted average diluted shares fell to 79.7 million from 85.6 million, supporting the adjusted EPS increase, but operating cash flow declined to $117.7 million from $138.1 million and cash balances fell to $311.9 million from $375.2 million at year-end. The company spent $83.0 million on repurchases during the quarter, so the EPS beat reflects both operating performance and a smaller share count.

Bottom line: This is a modestly better-than-expected quarter with a meaningful raise to the EBITDA floor, but the underlying operating story is not clean: same-unit growth is thin and costs are still outrunning revenue. The event advances the turnaround, though it does not yet prove durable margin expansion.

Original filing on SEC EDGAR

Pediatrix earnings beat as EBITDA slips, outlook floor rises | MD Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.